Definiens, Munich Germany, has partnered with Indivumed, Hamburg, Germany, to offer a combination of tissue-based biomarker validation and assay development, using the Definiens Cognition Network technology for image analysis and data mining.

The partnership will allow researchers and clinicians in oncology to tap into a joint offering of Indivumed’s cancer database, biobank, and analytical laboratory services for tissue analysis, together with Definiens’ proprietary Cognition Network technology and Tissue Phenomics approach to oncology and diagnostics. Indiviumed specializes in stringent and standardized tissue collection processes that preserve biomolecules such as RNA and protein, allowing more accurate assessment of tissue patterns and more rigorous comparisons across samples.

Hartmut Juhl, Indivumed.

Hartmut Juhl, PhD, Indivumed.

“Customers of either company can now benefit from this partnership and our comprehensive approach for image analysis and tissue-based research and development in oncology,” says Hartmut Juhl, PhD, founder and chief executive of Indivumed.

Ralf Huss, MD, Definiens.

Ralf Huss, MD, Definiens.

“In the quest to use tissue biomarkers to create diagnostic tests for cancer patients, there is no question that the quality of tissue combined with advanced image analysis and tissue mining is extremely important,” says Ralf Huss, MD, chief medical officer at Definiens. “This partnership allows researchers and clinicians to benefit from the expertise of both our companies and advance personalized medicine for the treatment of patients. It will be great to see this partnership benefit not only researchers and clinicians, but also ultimately cancer patients.”

For more information, visit Definiens or Indivumed.